Harvard Bioscience IncHBIO

Harvard Bioscience Inc. last week reminded the market that its Incub8™ Multiwell MEA System can record electrophysiological and optical data from inside a humidified incubator, a neat trick that lets researchers keep cells happy while collecting signals. The filing reality is less glamorous: for the quarter to March 31, the company booked $20.8 million of revenue but still lost $3.4 million, while cash burned $662,000 in operations and inventory climbed $1.5 million to $22.2 million. With liabilities of $67.9 million against just $10 million in shareholders’ equity, the optics look like a service company that keeps promising an extra pair of hands while its own balance sheet keeps needing another.

Harvard Bioscience sells service-and-support packages for lab systems from DSI, BTX, Multi Channel Systems, Biochrom, HEKA, Harvard Apparatus, Panlab, Warner Instruments, CMA and Hugo Sachs Elektronik, offering “an extra set of hands from start to finish.” The prose is polished; the cash flow is not. Free cash flow was negative $662,000 in the quarter, capital spending $426,000, and R&D expense $2.3 million. One S-8 shelf filing on June 10 and four ownership XMLs on June 11-12 show the company has been busy on the filing rails, but the headline numbers remain stubbornly cash-flow negative.

Revenue of $20.8 million for the quarter to March 31 was not enough to offset a $3.4 million net loss, an operating loss of $1.2 million, and a diluted loss per share of $0.77 on 4.5 million diluted shares. Cash and equivalents were $7.1 million, liabilities $67.9 million, and shareholders’ equity $10.0 million. Inventory rose $1.5 million to $22.2 million, the standard product warranty accrual added $13,000, and the company spent $426,000 on property, plant and equipment. These are the numbers that sit beneath the polished brochures for IQ/OQ field validation services and service-and-support packages.

The company’s filings can be tracked on SEC EDGAR under CIK 1123494, with the latest 10-Q for the period ending March 31, 2026, the S-8 shelf filed June 10, 2026, and four ownership XMLs filed June 11-12, 2026. Product pages for the IQ/OQ field validation services, service-and-support packages, and the Incub8™ Multiwell MEA System illustrate the firm’s marketed offerings, but the financials remain the primary evidence. There is no guidance in the supplied filings.

The company’s market mechanism is the NASDAQ-listed equity Harvard Bioscience Inc., ticker HBIO. Trading context and chart levels are available via standard market data providers; this report cites only the filings, product pages, and companyfacts JSON supplied in the evidence pack.

What changed this period is the $1.5 million inventory build and the $662,000 operating cash burn, which together put pressure on working capital and cash. What remains unproven is any sustained path to positive free cash flow or per-share profitability under the current operating model. Evidence that would deepen the file includes a quarter with positive operating cash flow, a reduction in inventory relative to revenue, segment-level profitability, or updated guidance in a subsequent 10-Q or 8-K.